US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily Biotech Top 5 Bull 2X ETF

45.85

+1.673.79%

Volume:2K

Turnover:95.66K

Market Cap:5.73M

PE:- -

High:45.88

Open:44.96

Low:44.81

Close:44.17

52wk High:45.88

52wk Low:25.71

Shares:125.00K

Float Shares:125.00K

Volume Ratio:1.06

T/O Rate:1.68%

Dividend:0.62

Dividend Rate:1.36%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

EU Commission Approves Gilead Trodelvy-Keytruda Combo for First-Line PD-L1+ Metastatic TNBC

Gilead - EU Grants Marketing Authorization for Trodelvy with Keytruda in First-Line Pd-L1-Positive Metastatic Tnbc

THOMSON REUTERS

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across Pd-L1 Status

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)

Daiichi Sankyo Names Ken Keller Chief Commercialization Officer, Effective April 2027

Is Viavi Solutions (VIAV) Quietly Recasting Its 6G Moat With the Vertex 6.0 Launch?

Simply Wall St.

Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In?

Simply Wall St.

Funds: What a Top Biotech Fund is Buying Now

Gilead Director Jeffrey Bluestone Disposes of 5,000 Common Shares Worth $727,333.60

Moderna Inc. Stock Advances 8.9%, Outperforms Peers

Gilead Declares Q3 2026 Dividend of R$ 0.24 Per Unit

Amgen Advances Tarlatamab Shot vs. Infusion in Phase 3 Lung Cancer Study

Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims

CStone Gains Rapid China IND Approval for EGFR/HER3 ADC CS5007

Gilead (GILD) Stock Still Looks Below Fair Value As Court Backs HIV Import Block

Simply Wall St.

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors

Moderna Inc. Stock Slips 23.5%, Underperforms Peers

Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial

Regeneron’s Pasatru granted FDA approval for FOP

Wall Street Analysts Are Bullish on Top Healthcare Picks

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/TBXU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TBXU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TBXU\",,,,,undefined,":{"symbol":"TBXU","market":"US","secType":"STK","nameCN":"Direxion Daily Biotech Top 5 Bull 2X ETF","latestPrice":45.8456,"timestamp":1788379200000,"preClose":44.172,"halted":0,"volume":2099,"delay":0,"changeRate":0.03788825500316944,"floatShares":125000,"shares":125000,"eps":0,"marketStatus":"Pre-Mkt","change":1.6736,"latestTime":"09-03 05:01:57 EDT","open":44.96,"high":45.88,"low":44.81,"amount":95658.868856,"amplitude":0.024223,"askPrice":72.89,"askSize":100,"bidPrice":18.43,"bidSize":100,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788442200000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":45.8456,"sharesOutstanding":100001,"nav":44.235,"aum":5529447.64,"dividendRate":0.013563,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":45.88,"preClose":45.8456,"latestTime":"18:07 EDT","volume":11,"amount":509.5236,"timestamp":1788386861384,"change":0.0344,"changeRate":0.00075,"amplitude":0},"volumeRatio":1.0594589137896224},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TBXU\",,,,,undefined,":{"symbol":"TBXU","floatShares":125000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0594589137896224,"shares":125000,"dividePrice":0.6218,"high":45.88,"amplitude":0.024223,"preClose":44.172,"low":44.81,"week52Low":25.71,"pbRate":"--","week52High":45.88,"institutionHeld":0,"latestPrice":45.8456,"eps":0,"divideRate":0.013563,"volume":2099,"delay":0,"ttmEps":0,"open":44.96,"prevYearClose":31.065,"prevWeekClose":42.5761,"prevMonthClose":42.9245,"prevQuarterClose":32.1223,"fiveDayClose":44.3509,"twentyDayClose":35.755,"sixtyDayClose":29.6232},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TBXU\",params:#limit:5,,,undefined,":[{"date":"2026-06-23","symbol":"TBXU","amount":0.11101,"announcedDate":"2026-06-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-23","defaultRemindTime":1782221400000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-23","currency":"USD","dateTimestamp":1782187200000,"payDate":"2026-06-30"},{"date":"2026-03-24","symbol":"TBXU","amount":0.09893,"announcedDate":"2026-03-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-24","defaultRemindTime":1774359000000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-24","currency":"USD","dateTimestamp":1774324800000,"payDate":"2026-03-31"},{"date":"2025-12-23","symbol":"TBXU","amount":0.10111,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-31"},{"date":"2025-12-10","symbol":"TBXU","amount":0.31143,"announcedDate":"2025-12-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-10","defaultRemindTime":1765377000000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-17","payableDate":"2025-12-10","currency":"USD","dateTimestamp":1765342800000,"payDate":"2025-12-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TBXU\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-10","recordDate":"2025-12-10","paymentDate":"2025-12-17","value":0.31143,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-31","value":0.10111,"currency":"USD"},{"executeDate":"2026-03-24","recordDate":"2026-03-24","paymentDate":"2026-03-31","value":0.09893,"currency":"USD"},{"executeDate":"2026-06-23","recordDate":"2026-06-23","paymentDate":"2026-06-30","value":0.11101,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TBXU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TBXU\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661278374","title":"EU Commission Approves Gilead Trodelvy-Keytruda Combo for First-Line PD-L1+ Metastatic TNBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2661278374","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661278374?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:31","pubTimestamp":1787567503,"startTime":"0","endTime":"0","summary":"EU Commission approves Gilead Trodelvy-Keytruda combo for first-line PD-L1+ metastatic TNBCEuropean Commission granted marketing authorization for Trodelvy with Merck’s Keytruda in first-line metastat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL4gZS8y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","LU0109394709.USD","TBXU","LU2468319806.SGD","MEDI","LU2089984988.USD","LU0882574055.USD","IE00B3T34201.USD","LU1934455277.USD","BK4583","IBB","BK4566","LU1066051498.USD","LU1061106388.HKD","LU1674673691.USD","LU2357627491.SGD","GILD","LU0058720904.USD","SG9999015978.USD","LU1571399168.USD","LU1057294990.SGD","BK4585","LU0289739699.SGD","LU1778281490.HKD","BBH","LU1023059063.AUD","LU1585245621.USD","LU0965509101.SGD","BMED","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU0114720955.EUR","LU1934455863.HKD","LU1037948897.HKD","BK4550","LU0965508806.USD","LU0320765992.SGD","LU0823416689.USD","LU1037948541.HKD","IBBQ","LU0861579265.USD","IE00BZ1G4Q59.USD","LU0965509283.SGD","LU0965509010.AUD","LU1934455194.USD","IE0002270589.USD","LU0859254822.USD","SG9999015986.USD","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661325278","title":"Gilead - EU Grants Marketing Authorization for Trodelvy with Keytruda in First-Line Pd-L1-Positive Metastatic Tnbc","url":"https://stock-news.laohu8.com/highlight/detail?id=2661325278","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661325278?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:31","pubTimestamp":1787567460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUAMP4X3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1066051498.USD","BMED","BK4568","BK4550","LU1585245621.USD","LU0289739699.SGD","IE00B3T34201.USD","IE00B7SZLL34.SGD","IE0002270589.USD","BK4139","LU1934455277.USD","LU2357627491.SGD","GILD","LU0320765992.SGD","LU2324357040.USD","MEDI","LU1674673428.USD","IBB","LU1934455194.USD","LU1057294990.SGD","LU1839511570.USD","LU1037948897.HKD","LU0965509283.SGD","BK4585","LU1674673691.USD","BBH","LU1934455863.HKD","BK4588","LU0889565916.HKD","IE00B19Z3B42.SGD","LU0965508806.USD","TBXU","IE00BSNM7G36.USD","LU2468319806.SGD","LU0965509010.AUD","SG9999015986.USD","SG9999015945.SGD","BK4566","LU0058720904.USD","BIB","LU1023059063.AUD","LU1061106388.HKD","IBBQ","LU1066053197.SGD","TMED","LU0234570918.USD","LU0965509101.SGD","SG9999015978.USD","SG9999015952.SGD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661278323","title":"European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across Pd-L1 Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2661278323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661278323?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:31","pubTimestamp":1787567460,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUAMP4X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBBQ","LU1037948897.HKD","GILD","LU2357627491.SGD","TMED","BBH","LU2324357040.USD","LU0320765992.SGD","LU0122379950.USD","LU0965509101.SGD","LU1585245621.USD","SG9999015945.SGD","LU0234570918.USD","LU2089984988.USD","MEDI","LU1674673691.USD","IE00B19Z3B42.SGD","TBXU","BK4532","LU0859254822.USD","LU1934455863.HKD","SG9999015978.USD","LU0058720904.USD","BIB","IE00BKVL7J92.USD","BMED","LU0823416689.USD","LU1061106388.HKD","LU1037948541.HKD","BK4566","LU0289739699.SGD","BK4585","SG9999015986.USD","LU1057294990.SGD","IBB","BK4588","LU0114720955.EUR","BK4568","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU0861579265.USD","BK4583","BK4139","LU0109394709.USD","LU1066053197.SGD","LU2087621335.USD","SG9999015952.SGD","LU0889565916.HKD","LU1674673428.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661784220","title":"Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661784220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661784220?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:20","pubTimestamp":1787566808,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enliven Therapeutics (ELVN), Argenx Se (ARGX) and Aq...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-enliven-therapeutics-elvn-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-enliven-therapeutics-elvn-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","ARGX","LU2324357040.USD","IE0009355771.USD","TBXU","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BFTCPJ56.SGD","BK4588","BK4585","LU1983260115.SGD","IE00B2B36J28.USD","LU0889565916.HKD","IE0034235188.USD","BK4007","IE00BJJMRZ35.SGD","BK4505","IE0002141913.USD","BK4139","ELVN","IBB","FMED","LU0823416689.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661222504","title":"Daiichi Sankyo Names Ken Keller Chief Commercialization Officer, Effective April 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2661222504","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661222504?lang=en_us&edition=fundamental","pubTime":"2026-08-24 15:00","pubTimestamp":1787554851,"startTime":"0","endTime":"0","summary":"Daiichi Sankyo names Ken Keller chief commercialization officer, effective April 2027Daiichi Sankyo named Ken Keller chief commercialization officer, effective April 1, 2027, to run a new globally int","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDLbyMxfX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0868494617.USD","LU0320765992.SGD","LU0058720904.USD","AMGN","TBXU","LU0109394709.USD","LU2468319806.SGD","BK4588","LU1061106388.HKD","LU1057294990.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BIB","LU1983299246.USD","LU0122379950.USD","PBE","LU2112291526.USD","IBB","IE00B2B36J28.USD","BK4534","LU2089984988.USD","BK4599","LU0889565916.HKD","BBH","LU2242646821.SGD","IBBQ","PJP","LU1023059063.AUD","BK4581","IE0009355771.USD","IE00B4R5TH58.HKD","BK4566","SG9999001440.SGD","BK4139","IE0002141913.USD","LU1571399168.USD","BK4585","LU2242652126.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661228075","title":"Is Viavi Solutions (VIAV) Quietly Recasting Its 6G Moat With the Vertex 6.0 Launch?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661228075","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661228075?lang=en_us&edition=fundamental","pubTime":"2026-08-24 11:29","pubTimestamp":1787542174,"startTime":"0","endTime":"0","summary":"Earlier in August 2026, VIAVI Solutions launched Vertex 6.0, an enhanced channel emulation platform with 400 MHz instantaneous bandwidth and support for carrier frequencies up to 23.6 GHz, targeting next-generation 6G and Wi‑Fi 7/8 testing and integrating real-world RF propagation into lab environments.\nThis upgrade, the first since acquiring Spirent’s high-speed Ethernet, network security and channel emulation testing business, positions Vertex 6.0 as a modular RF digital twin platform...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8111000-choice1-main-header/1585186745276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8111000-choice1-main-header/1585186745276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/tech/nasdaq-viav/viavi-solutions/news/is-viavi-solutions-viav-quietly-recasting-its-6g-moat-with-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/tech/nasdaq-viav/viavi-solutions/news/is-viavi-solutions-viav-quietly-recasting-its-6g-moat-with-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0109394709.USD","VRTX","IBBQ","LU2065171402.SGD","CHAT","SG9999013999.USD","LU0432979614.USD","LU0889565916.HKD","LU0417517546.SGD","VIAG","VTHR","LU0234570918.USD","LU1585245621.USD","LU1069344957.HKD","LU2417539215.USD","LU1559883803.SGD","BK4585","BK4588","LU2362540622.SGD","IE0002141913.USD","BIB","QTOC","TBXU","AIPO","IE00B19Z9Z06.USD","BK4023","LU1674673428.USD","LU2462157665.USD","LU2065171311.SGD","LU2089984988.USD","LU2236285917.USD","VERX","SG9999001176.SGD","LU0240877869.USD","BBH","IBB","IE00B2B36J28.USD","LU0061475181.USD","VIAV","AGIX","LU1093756325.SGD","PBE","IE00B4R5TH58.HKD","BK4567","GNMX","IDNA","LU0205194284.USD","ARTY","LU2065170008.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661302215","title":"Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661302215","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661302215?lang=en_us&edition=fundamental","pubTime":"2026-08-22 09:30","pubTimestamp":1787362233,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) stock moved after the U.S. Food and Drug Administration approved Pasatru for adults with fibrodysplasia ossificans progressiva. This new rare disease therapy is supported by late stage OPTIMA trial data.\nSee our latest analysis for Regeneron Pharmaceuticals.\nThe Pasatru approval comes after a strong run in Regeneron Pharmaceuticals’ stock, with a 30.55% 90 day share price return and a 42.21% 1 year total shareholder return, suggesting recent momentum after...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-wins-pasatru-approval-is-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-wins-pasatru-approval-is-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2237438978.USD","LU0823434583.USD","LU2023250504.SGD","LU0882574055.USD","LU2362541273.HKD","LU2468319806.SGD","LU2362540622.SGD","LU0289739699.SGD","LU2362541513.USD","DCF","LU0114720955.EUR","LU0053666078.USD","LU0823434740.USD","BK4139","LU0320765992.SGD","BK4585","LU0109394709.USD","LU2089984988.USD","REGN","LU1917777945.USD","LU0889565916.HKD","BBH","BK4588","TBXU","LU0058720904.USD","LU1974910355.USD","IBBQ","LU2106854487.HKD","IBB","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661213210","title":"Funds: What a Top Biotech Fund is Buying Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2661213210","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661213210?lang=en_us&edition=fundamental","pubTime":"2026-08-22 09:30","pubTimestamp":1787362200,"startTime":"0","endTime":"0","summary":"It's hard to find a more experienced biotech investor than Evan McCulloch. The manager of Franklin Biotechnology Discovery has been running the $1.2 billion fund since 1997.That matters in this highly","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0889565916.HKD","SGXZ57979304.SGD","BK4585","LU2417539215.USD","SG9999015986.USD","BK4139","LU2456880835.USD","LU0154245756.USD","LU1983299246.USD","IE00B19Z3B42.SGD","SG9999015978.USD","IE00BZ9MQY76.HKD","LU2237438978.USD","LU1023059063.AUD","IDNA","LU1037948541.HKD","BBH","IE00BKVL7J92.USD","LU1571399168.USD","LU0122379950.USD","SG9999001176.USD","BK4007","LU1934455863.HKD","BK4599","IE00BN0W2W23.USD","LU1974910355.USD","BK4588","LU2236285917.USD","JAZZ","LU0114720955.EUR","LU1066051498.USD","LU0417517546.SGD","BK4533","LU0234570918.USD","IBB","IE00BSNM7G36.USD","IE0002141913.USD","LU1035775433.USD","LU0965509283.SGD","AMGN","LU2023250504.SGD","MEDI","BK4567","LU1934455194.USD","LU0053666078.USD","SG9999001176.SGD","IE00BJT1NW94.SGD","LU1069344957.HKD","SG9999015952.SGD","LU2242646821.SGD","LU2089984988.USD","LU0432979614.USD","LU1430594728.SGD","LU0823416689.USD","VRTX","IE00BFTCPJ56.SGD","IE00B19Z3581.USD","BK4532","LU2112291526.USD","LU1037948897.HKD","BK4550","LU1066053197.SGD","IE00BZ1G4Q59.USD","XBI","LU0289739699.SGD","BK4583","LU0882574055.USD","LU1839511570.USD","LU0058720904.USD","LU2242652126.USD","SG9999001440.SGD","BK4578","04332","SG9999013999.USD","LU1674673428.USD","LU0256863811.USD","LU2462157665.USD","IE00B19Z9Z06.USD","LU1093756325.SGD","BK4566","LU2106854487.HKD","LU1778281490.HKD","IE00B3T34201.USD","SG9999015945.SGD","IBBQ","LU2362541273.HKD","LU0861579265.USD","LU0154245673.USD","BIB","GNMX","LU0868494617.USD","LU1934455277.USD","TBXU","LU1057294990.SGD","LU2362540622.SGD","LU0061475181.USD","IE00B19Z9P08.USD","IE00B2B36J28.USD","IE00B7SZLL34.SGD","LU0859254822.USD","LU0823434740.USD","BMED","IE00BN0W2V16.EUR","LU1917777945.USD","IE00B894F039.SGD","LU1093756168.USD","PBE","BK4581","LU0079474960.USD","LU0109394709.USD","LU0823434583.USD","LU0965509101.SGD","IE0002270589.USD","LU1585245621.USD","REGN","PJP","IE00B4R5TH58.HKD","LU2324357040.USD","GILD","LU0965509010.AUD","LU1061106388.HKD","IE0009355771.USD","TMED","LU2362541513.USD","LU2357627491.SGD","LU2468319806.SGD","LU0965508806.USD","LU1674673691.USD","BK4534","LU2087621335.USD","IE00BN0W2T93.GBP","IE00BJJMRZ35.SGD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661187372","title":"Gilead Director Jeffrey Bluestone Disposes of 5,000 Common Shares Worth $727,333.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2661187372","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661187372?lang=en_us&edition=fundamental","pubTime":"2026-08-22 07:22","pubTimestamp":1787354576,"startTime":"0","endTime":"0","summary":"Gilead director Jeffrey Bluestone disposes of 5,000 common shares worth $727,333.60Gilead director Jeffrey Bluestone exercised stock options on Aug. 20, 2026, acquiring 5,000 shares at USD 61.35 to US","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4cgVd7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead Director Jeffrey Bluestone Disposes of 5,000 Common Shares Worth $727,333.60","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","BK4568","LU0058720904.USD","IBBQ","LU1674673691.USD","MEDI","LU0234570918.USD","LU2357627491.SGD","LU1585245621.USD","LU1430594728.SGD","SG9999015978.USD","IE00B19Z3581.USD","TBXU","BK4532","BK4583","IE00BSNM7G36.USD","LU0122379950.USD","LU1057294990.SGD","LU1674673428.USD","LU1778281490.HKD","TMED","IE00B3T34201.USD","LU0965509101.SGD","LU0320765992.SGD","LU0861579265.USD","BK4588","LU1571399168.USD","BK4566","LU0859254822.USD","IE00B19Z3B42.SGD","LU0882574055.USD","SG9999015945.SGD","LU0965509010.AUD","LU1023059063.AUD","BMED","LU0289739699.SGD","IE00B7SZLL34.SGD","SG9999015952.SGD","IBB","GILD","BIB","LU1934455863.HKD","BK4139","LU2089984988.USD","LU0965509283.SGD","SG9999015986.USD","LU0965508806.USD","LU1066053197.SGD","BBH","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661972042","title":"Moderna Inc. Stock Advances 8.9%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2661972042","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661972042?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:33","pubTimestamp":1787344380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. rose 8.9% to $145.13 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 0.4% to 26,180.45 and the Dow Jones Industrial Average rising 1.0% to 53,277.01.Moderna Inc. closed 17.8% below its 52-week high of $176.66, which the company reached on August 19th.The stock outperformed some of its peers, as Johnson & Johnson rose 1.1% to $270.24, Pfizer Inc. rose 1.0% to $28.07, and Gilead Sciences Inc. rose 1.87% to $146.12.Trading volume totaled 86.7 million, compared to the 50-day average of 13.0 million.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","IE0002270589.USD","GILD","LU0965509010.AUD","LU1839511570.USD","LU2357627491.SGD","TMED","BBH","LU1571399168.USD","MRNY","BK4501","LU0320765992.SGD","GNOM","LU1430594728.SGD","LU2324357040.USD","LU0122379950.USD","LU1585245621.USD","LGHT","LU0234570918.USD","MEDI","LU1674673691.USD","MRNX","TBXU","BK4532","LU1934455863.HKD","SG9999015978.USD","LU0058720904.USD","MRNA","BIB","LU0823416689.USD","BMED","LU1061106388.HKD","LU2112291526.USD","WDNA","LU1037948541.HKD","BK4551","LU1934455194.USD","LU0289739699.SGD","BK4585","IDNA","LU1057294990.SGD","SG9999015986.USD","BK4550","LU0965509283.SGD","IBB","LU1066053197.SGD","LU0861579265.USD","BK4583","SG9999015952.SGD","LU0965508806.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661940352","title":"Gilead Declares Q3 2026 Dividend of R$ 0.24 Per Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2661940352","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661940352?lang=en_us&edition=fundamental","pubTime":"2026-08-22 01:58","pubTimestamp":1787335117,"startTime":"0","endTime":"0","summary":"Gilead declares Q3 2026 dividend of R$ 0.24 per unitGilead Sciences set a Q3 2026 distribution of R$ 0.24 per unit for BRGILDBDR 000.Last day to trade with rights: Sept. 11, 2026.Payment date: Oct. 5,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL12Yy9R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0965509283.SGD","BK4578","IE00B7SZLL34.SGD","BK4583","TMED","LU0114720955.EUR","LU0823416689.USD","SG9999015986.USD","LU2468319806.SGD","LU1674673691.USD","BK4139","LU0965509010.AUD","MEDI","LU1430594728.SGD","SG9999015952.SGD","LU0965509101.SGD","LU2324357040.USD","LU2357627491.SGD","IE00B3T34201.USD","TBXU","IE0002270589.USD","LU0859254822.USD","LU0122379950.USD","LU1061106388.HKD","LU1037948897.HKD","LU1023059063.AUD","BK4588","IE00BKVL7J92.USD","LU0965508806.USD","LU2089984988.USD","BK4550","LU2112291526.USD","LU1037948541.HKD","IBBQ","LU1674673428.USD","LU1066053197.SGD","BK4585","BK4532","GILD","LU1585245621.USD","BK4568","LU0889565916.HKD","LU0320765992.SGD","BIB","IBB","BBH","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661887294","title":"Amgen Advances Tarlatamab Shot vs. Infusion in Phase 3 Lung Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2661887294","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661887294?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:34","pubTimestamp":1787330049,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s new Phase 3 DeLLphi-315 study tests its cancer drug tarlatamab in pe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgen-advances-tarlatamab-shot-vs-infusion-in-phase-3-lung-cancer-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgen-advances-tarlatamab-shot-vs-infusion-in-phase-3-lung-cancer-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU2242646821.SGD","BK4588","BBH","PJP","LU2242652126.USD","LU0868494617.USD","BK4566","IBB","IE00B2B36J28.USD","LU0122379950.USD","BK4533","IE00B4R5TH58.HKD","BK4139","IE00BJT1NW94.SGD","IE0002141913.USD","LU1571399168.USD","BK4585","LU2089984988.USD","TBXU","AMGN","IE00BJJMRZ35.SGD","BK4534","PBE","LU1061106388.HKD","BIB","LU0889565916.HKD","IE0009355771.USD","LU1023059063.AUD","LU1057294990.SGD","IBBQ","LU2112291526.USD","BK4599","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU0320765992.SGD","LU0289739699.SGD","LU1983299246.USD","LU0058720904.USD","SG9999001440.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260437","title":"Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260437?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:58","pubTimestamp":1787313533,"startTime":"0","endTime":"0","summary":"A class action lawsuit was filed against biotechnology company Regeneron ($REGN) on July 16, which could put further pressure on its troubled share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/regeneron-stock-regn-buckling-as-shareholders-sue-over-cancer-drug-claims?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/regeneron-stock-regn-buckling-as-shareholders-sue-over-cancer-drug-claims?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","AGNG","REGN","BBH","IBB","XT","LU2023250504.SGD","LU2237438978.USD","BK4139","JDOC","BK4585","LU2362541273.HKD","LU2089984988.USD","TBXU","LU0114720955.EUR","BBP","LU2106854487.HKD","LU0053666078.USD","LNGR","FHLC","DARP","LU0823434740.USD","LU0889565916.HKD","LU2362540622.SGD","LU2362541513.USD","RSPH","IEIH","IBBQ","LU1917777945.USD","FWD","LU2468319806.SGD","LU0320765992.SGD","LU0823416689.USD","LU0289739699.SGD","LU1974910355.USD","LU0882574055.USD","LU0823434583.USD","LU0058720904.USD","LU0109394709.USD","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661302932","title":"CStone Gains Rapid China IND Approval for EGFR/HER3 ADC CS5007","url":"https://stock-news.laohu8.com/highlight/detail?id=2661302932","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661302932?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:07","pubTimestamp":1787263635,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals ( ($HK:2616) ) just unveiled an announcement. CStone Pharmaceuticals has secured rapid investigational new drug approval in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cstone-gains-rapid-china-ind-approval-for-egfr-her3-adc-cs5007?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cstone-gains-rapid-china-ind-approval-for-egfr-her3-adc-cs5007?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4231","TBXU","ADC","IND","NETL","PSIL","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661923014","title":"Gilead (GILD) Stock Still Looks Below Fair Value As Court Backs HIV Import Block","url":"https://stock-news.laohu8.com/highlight/detail?id=2661923014","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661923014?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:35","pubTimestamp":1787258134,"startTime":"0","endTime":"0","summary":"Gilead Sciences stock has delivered very strong long term returns over the past five years, yet current valuation checks and market multiples still point to the shares screening as undervalued. With recent news flow focused on its HIV and oncology franchises and on legal protection of its U.S. drug pricing, investors are weighing how much of this is already reflected in the price.\n\nGilead Sciences has returned 148.1% over the past five years, which puts recent valuation questions in the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-still-looks-below-fair-value-as-court-back","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-still-looks-below-fair-value-as-court-back","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1430594728.SGD","LU0965509010.AUD","LU2112291526.USD","LU0122379950.USD","IE00BKVL7J92.USD","GILD","BK4550","SG9999015986.USD","LU1934455194.USD","LU1934455277.USD","LU0114720955.EUR","IBBQ","IBB","IE00BSNM7G36.USD","LU2089984988.USD","LU0965509283.SGD","CDIG","LU1934455863.HKD","LU1057294990.SGD","BK4566","MEDI","LU2087621335.USD","LU1037948541.HKD","BK4588","LU0861579265.USD","IE00BZ1G4Q59.USD","LU1066051498.USD","LU0823416689.USD","BMED","LU1778281490.HKD","LU0889565916.HKD","IE00B19Z3581.USD","IE0002270589.USD","LU0109394709.USD","LU0965508806.USD","TACU","TMED","IE00B19Z3B42.SGD","SG9999015945.SGD","TSPA","BK4585","BBH","LU1037948897.HKD","TBXU","SG9999015978.USD","DAPP","LU0320765992.SGD","LU2468319806.SGD","LU0289739699.SGD","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661232279","title":"Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661232279","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661232279?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:35","pubTimestamp":1787258100,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Thursday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  slipped 2.82% to $143.44 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 0.87% to 7,641.16 and Dow Jones Industrial Average  falling 1.32% to 52,759.21.The stock's fall snapped a seven-day winning streak.Gilead Sciences Inc. closed 8.81% below its 52-week high of $157.29, which the company achieved on February 11th.The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson  fell 2.21% to $267.37, Pfizer Inc.  fell 1.59% to $27.79, and Abbott Laboratories  fell 0.25% to $114.14.Trading volume  remained 286,153 below its 50-day average volume of 7.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled August 20, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0965509283.SGD","LU1934455277.USD","BK4578","IE00B7SZLL34.SGD","LU0109394709.USD","BK4583","SG9999015978.USD","LU0861579265.USD","TMED","LU0114720955.EUR","LU0823416689.USD","SG9999015986.USD","LU2468319806.SGD","LU1674673691.USD","BK4139","LU0965509010.AUD","LU1571399168.USD","LU2087621335.USD","MEDI","LU1430594728.SGD","SG9999015952.SGD","LU0965509101.SGD","LU2324357040.USD","IE00B3T34201.USD","LU1839511570.USD","LU1934455194.USD","IE00BZ1G4Q59.USD","TBXU","IE0002270589.USD","LU0122379950.USD","LU1061106388.HKD","LU1037948897.HKD","LU1934455863.HKD","LU1023059063.AUD","LU1066051498.USD","BK4588","IE00BKVL7J92.USD","LU0965508806.USD","LU2089984988.USD","LU0058720904.USD","BK4550","LU1778281490.HKD","LU2112291526.USD","LU1037948541.HKD","IBBQ","LU1674673428.USD","LU1066053197.SGD","LU0289739699.SGD","IE00B19Z3581.USD","BK4585","LU0234570918.USD","SG9999015945.SGD","BK4532","GILD","LU1057294990.SGD","LU1585245621.USD","BK4568","LU0889565916.HKD","LU0320765992.SGD","BIB","IBB","BK4566","BBH","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661232427","title":"Moderna Inc. Stock Slips 23.5%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2661232427","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661232427?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:33","pubTimestamp":1787257980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. cratered 23.5% to $133.32 on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 1.0% to 26,067.17 and Dow Jones Industrial Average falling 1.3% to 52,759.21.Moderna Inc. closed 24.5% short of its 52-week high of $176.66, which the company reached on August 19th.The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 2.2% to $267.37, Pfizer Inc. fell 1.6% to $27.79, and Gilead Sciences Inc. fell 2.82% to $143.44.Trading volume totaled 97.3 million, compared to the 50-day average of 11.2 million.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0823416689.USD","MRNA","LU1430594728.SGD","LU0289739699.SGD","LU0882574055.USD","LGHT","SG9999015945.SGD","TMED","LU1037948541.HKD","LU1585245621.USD","BK4566","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","LU0109394709.USD","BIB","BBH","IDNA","BK4551","BMED","GILD","IE00BSNM7G36.USD","BK4578","BK4532","LU1066053197.SGD","LU0058720904.USD","LU1023059063.AUD","LU1934455194.USD","LU1778281490.HKD","LU2324357040.USD","LU2468319806.SGD","IBB","LU1839511570.USD","MEDI","TBXU","BK4139","LU2112291526.USD","SG9999015952.SGD","IBBQ","BK4533","MRNX","LU0114720955.EUR","MRNY","LU1674673428.USD","LU1674673691.USD","WDNA","GNOM","BK4548","LU0965509010.AUD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661323699","title":"Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661323699","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661323699?lang=en_us&edition=fundamental","pubTime":"2026-08-21 00:30","pubTimestamp":1787243431,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals Inc. ($VRTX) announced an update on their ongoing clinical study. The Phase 2b study A Phase 2b, Open-label Study to Evaluat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-advances-kidney-disease-pipeline-with-completed-inaxaplin-phase-2b-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-advances-kidney-disease-pipeline-with-completed-inaxaplin-phase-2b-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERX","LU2362541513.USD","LU1674673428.USD","LU2362540622.SGD","BK4567","IBBQ","BK4588","IE00B19Z9P08.USD","SG9999001176.USD","LU0757428866.USD","IE00BJJMRZ35.SGD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IDNA","IE00B19Z3581.USD","LU2324357040.USD","SG9999013999.USD","LU0566484027.USD","TBXU","VRTX","BK4139","LU2362541273.HKD","PBE","LU1093756325.SGD","LU1815336091.USD","LU0234570918.USD","LU2417539215.USD","LU1093756168.USD","IE0002141913.USD","LU2468319806.SGD","BK4585","LU1069344957.HKD","LU2456880835.USD","LU1674673691.USD","LU0289739699.SGD","LU0256863811.USD","LU0079474960.USD","BIB","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2237438978.USD","IE00B894F039.SGD","SG9999001176.SGD","BBH","LU2089984988.USD","LU0432979614.USD","IBB","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287604","title":"Regeneron’s Pasatru granted FDA approval for FOP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287604","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287604?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:20","pubTimestamp":1787232025,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has approved Pasatru to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","IBB","IDNA","LABU","BBP","BK4585","FRTY","TBXU","PINK","IEIH","MEDI","LFSC","BK4588","GNMX","PSCH","MRNY","TECB","NVIB","GDOC","IYH","MRNX","BMED","RSPH","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660728971","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2660728971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660728971?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:40","pubTimestamp":1787226007,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vertex Pharmaceuticals (VRTX), Glaukos (GKOS) and Ve...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-306?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-306?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","LU1035775433.USD","BK4533","GKOS","LU0109394709.USD","TBXU","LU2468319806.SGD","LU2462157665.USD","LU0432979614.USD","BK4139","LU2089984988.USD","LU2362540622.SGD","IE0002141913.USD","IBB","IE00B2B36J28.USD","IE0009354923.USD","BK4548","LU1674673691.USD","LU0417517546.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU1093756168.USD","LU1878469433.USD","LU2362541513.USD","SG9999001176.SGD","IE00BZ9MQY76.HKD","BK4585","LU0289739699.SGD","BK4532","BBH","LU0079474960.USD","LU0889565916.HKD","LU1778281490.HKD","GNMX","IDNA","LU1585245621.USD","LU2236285917.USD","IE0009355771.USD","BK4588","LU0061475181.USD","LU1069344957.HKD","LU1430594728.SGD","SGXZ57979304.SGD","BIB","IE00B19Z3581.USD","IE00BJT1NW94.SGD","LU2324357040.USD","IE00B19Z9Z06.USD","LU2237438978.USD","SG9999013999.USD","LU0320765992.SGD","LU0823416689.USD","LU0234570918.USD","SG9999001176.USD","IE00B894F039.SGD","IBBQ","IE00B19Z3B42.SGD","LU2065731478.USD","PBE","LU1674673428.USD","IE00B4R5TH58.HKD","VRTX","IE00B19Z9P08.USD","LU2417539215.USD","LU2362541273.HKD","LU2456880835.USD","IE0002270589.USD","LU1093756325.SGD","BK4567","BK4082","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}